Haldol-Depot

Haldol-Depot is a depot formulation of the active ingredient haloperidol decanoate, supplied as an intramuscular injection. The product is marketed in the European Union and is classified as a prescription‑only antipsychotic belonging to the butyrophenone class. It is used for the management of schizophrenia and other chronic psychotic conditions, providing sustained drug release over several weeks.

Haldol-Depot is indicated for the treatment of schizophrenia and related psychotic disorders, particularly when long‑term maintenance therapy is required.

- Acute management of severe psychotic episodes requiring rapid symptom control. - Maintenance therapy to prevent relapse in chronic schizophrenia. - Adjunctive treatment for patients who have responded to oral haloperidol. - Situations where adherence to daily oral medication is challenging. - Use in combination with other antipsychotics when clinically justified.

Side effects of Haldol-Depot vary in frequency and severity. Patients should be monitored regularly for both common and serious reactions.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Drowsiness or sedation, especially after injection. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort. - Weight gain or changes in appetite. - Elevated prolactin levels leading to menstrual changes.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening condition. - Tardive dyskinesia with persistent involuntary movements. - Severe hypotension or cardiac arrhythmias. - Hyperglycemia or new‑onset diabetes mellitus. - Significant liver enzyme elevations. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Haldol-Depot, clinicians should evaluate patient history and monitor for potential risks.

- Assess for cardiovascular disease, as haloperidol may affect heart rhythm. - Screen for a history of seizures or neurologic disorders. - Monitor for signs of metabolic disturbances, including glucose and lipid changes. - Use caution in patients with hepatic or renal impairment. - Evaluate prolactin‑related effects, especially in women of childbearing age. - Discuss pregnancy and lactation considerations, as safety data are limited. - Ensure regular follow‑up to detect early signs of tardive dyskinesia.

Haldol-Depot can interact with several medication classes, influencing efficacy or safety.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk. - Medications that prolong QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole) that could raise haloperidol levels.

Use with caution: - CNS depressants, including benzodiazepines and opioids, for additive sedation. - Anticholinergic agents, which may mask extrapyramidal symptoms. - Drugs affecting glucose metabolism, such as insulin or oral hypoglycemics. - Medications that alter hepatic enzyme activity, like rifampin, which may reduce efficacy.